Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Owens & Minor

This article was originally published in The Gray Sheet

Executive Summary

Completes merger with Stuart Medical following shareholder approval on May 10. The Justice Department in February finished its antitrust review of the transaction, which was announced in December ("The Gray Sheet" Feb. 14, In Brief). Corporate management changes announced at the May 10 shareholder meeting include: G. Gilmer Minor, III named chairman, replacing G. Gilmer Minor, Jr., who becomes chairman emeritus; Carl Grefenstette, chair and CEO of the Hillman company, which previously owned most of Stuart Medical, joins O&M board; and former Stuart President and CEO Richard Byington becomes O&M executive vice president. Also promoted to executive VP are O&M's Robert Anderson, Henry Berling and Craig Smith. Thomas Sherry, formerly with Stuart, becomes Owens & Minor's VP, sales and marketing

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel